海创药业：关于公司通过药品GMP符合性检查暨药品生产许可证变更的公告

Core Viewpoint - Haichuang Pharmaceutical has received the GMP compliance inspection notice from the Sichuan Provincial Drug Administration, confirming that its soft capsule production line for the anti-tumor drug, Deutetrabenazine, meets the required quality management standards [1] Group 1 - The company announced the receipt of the GMP compliance inspection notice (No. 川许2026035) [1] - The inspection covered the soft capsule production line for the anti-tumor drug Deutetrabenazine (National Drug Approval No. H20250029) [1] - The company has completed the necessary changes to its drug production license following the successful inspection [1]